Clinigen Group PLC (CLIN) Given Average Rating of “Buy” by Brokerages

Shares of Clinigen Group PLC (LON:CLIN) have been given a consensus rating of “Buy” by the six analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is GBX 1,222.17 ($16.57).

Several brokerages recently issued reports on CLIN. N+1 Singer reissued a “buy” rating and set a GBX 1,225 ($16.61) price target on shares of Clinigen Group in a report on Wednesday. Peel Hunt reissued a “buy” rating and set a GBX 1,350 ($18.31) price target on shares of Clinigen Group in a report on Wednesday. Berenberg Bank raised shares of Clinigen Group to a “buy” rating and lifted their price target for the company from GBX 1,200 ($16.27) to GBX 1,220 ($16.54) in a report on Thursday. Numis Securities reissued an “add” rating and set a GBX 1,208 ($16.38) price target on shares of Clinigen Group in a report on Wednesday. Finally, Royal Bank of Canada reissued an “outperform” rating and set a GBX 1,360 ($18.44) price target on shares of Clinigen Group in a report on Tuesday, November 7th.

In other Clinigen Group news, insider Chris Rigg sold 4,955 shares of the firm’s stock in a transaction dated Thursday, November 23rd. The shares were sold at an average price of GBX 1,017 ($13.79), for a total value of £50,392.35 ($68,337.88).

Clinigen Group (LON CLIN) opened at GBX 1,059 ($14.36) on Friday. Clinigen Group has a 1-year low of GBX 751.50 ($10.19) and a 1-year high of GBX 1,187 ($16.10). The stock has a market cap of $1,300.00 and a PE ratio of 35,300.00.

COPYRIGHT VIOLATION WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/21/clinigen-group-plc-clin-given-average-rating-of-buy-by-brokerages.html.

About Clinigen Group

Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company’s principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.

Analyst Recommendations for Clinigen Group (LON:CLIN)

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply